Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer

Abstract This systematic review and cumulative analysis aimed to explore the efficacy and safety of the combination of intravesical mitomycin C (MMC) plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) patients. A comprehensive literature search using Pubmed, Embase, M...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tuo Deng, Bing Liu, Xiaolu Duan, Tao Zhang, Chao Cai, Guohua Zeng
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cd0b2ffac63d428fafd46ceb69e03ecd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cd0b2ffac63d428fafd46ceb69e03ecd
record_format	dspace
spelling	oai:doaj.org-article:cd0b2ffac63d428fafd46ceb69e03ecd2021-12-02T16:06:27ZSystematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer10.1038/s41598-017-03421-52045-2322https://doaj.org/article/cd0b2ffac63d428fafd46ceb69e03ecd2017-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-03421-5https://doaj.org/toc/2045-2322Abstract This systematic review and cumulative analysis aimed to explore the efficacy and safety of the combination of intravesical mitomycin C (MMC) plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) patients. A comprehensive literature search using Pubmed, Embase, Medline, Cochrane Library, CBM, CNKI and VIP databases was performed to identify studies applying intravesical MMC plus BCG therapy on NMIBC patients up to June 2016. Summarized unadjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the efficacy and safety of the combination therapy. A total of 25 studies containing 2749 NMIBC patients were included in this systematic review. Compared with BCG monotherapy, the combination therapy could significantly reduce the tumor recurrence rate (OR = 0.64, 95% CI: 0.44–0.94, P = 0.02) and cancer-specific mortality (OR = 0.54, 95% CI: 0.34–0.87, P = 0.01), without more toxicities (OR = 0.58, 95% CI: 0.17–1.94, P = 0.37). The combination therapy could also lead to significant lower tumor recurrence rate than MMC monotherapy (OR = 0.41, 95% CI: 0.24–0.69, P = 0.0009). Our study indicates that the combination of MMC plus BCG instillation is an effective and safe adjuvant treatment for NMIBC patients.Tuo DengBing LiuXiaolu DuanTao ZhangChao CaiGuohua ZengNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Tuo Deng Bing Liu Xiaolu Duan Tao Zhang Chao Cai Guohua Zeng Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
description	Abstract This systematic review and cumulative analysis aimed to explore the efficacy and safety of the combination of intravesical mitomycin C (MMC) plus bacillus Calmette-Guerin (BCG) for non-muscle-invasive bladder cancer (NMIBC) patients. A comprehensive literature search using Pubmed, Embase, Medline, Cochrane Library, CBM, CNKI and VIP databases was performed to identify studies applying intravesical MMC plus BCG therapy on NMIBC patients up to June 2016. Summarized unadjusted odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the efficacy and safety of the combination therapy. A total of 25 studies containing 2749 NMIBC patients were included in this systematic review. Compared with BCG monotherapy, the combination therapy could significantly reduce the tumor recurrence rate (OR = 0.64, 95% CI: 0.44–0.94, P = 0.02) and cancer-specific mortality (OR = 0.54, 95% CI: 0.34–0.87, P = 0.01), without more toxicities (OR = 0.58, 95% CI: 0.17–1.94, P = 0.37). The combination therapy could also lead to significant lower tumor recurrence rate than MMC monotherapy (OR = 0.41, 95% CI: 0.24–0.69, P = 0.0009). Our study indicates that the combination of MMC plus BCG instillation is an effective and safe adjuvant treatment for NMIBC patients.
format	article
author	Tuo Deng Bing Liu Xiaolu Duan Tao Zhang Chao Cai Guohua Zeng
author_facet	Tuo Deng Bing Liu Xiaolu Duan Tao Zhang Chao Cai Guohua Zeng
author_sort	Tuo Deng
title	Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
title_short	Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
title_full	Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
title_fullStr	Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
title_full_unstemmed	Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer
title_sort	systematic review and cumulative analysis of the combination of mitomycin c plus bacillus calmette-guérin (bcg) for non–muscle-invasive bladder cancer
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/cd0b2ffac63d428fafd46ceb69e03ecd
work_keys_str_mv	AT tuodeng systematicreviewandcumulativeanalysisofthecombinationofmitomycincplusbacilluscalmetteguerinbcgfornonmuscleinvasivebladdercancer AT bingliu systematicreviewandcumulativeanalysisofthecombinationofmitomycincplusbacilluscalmetteguerinbcgfornonmuscleinvasivebladdercancer AT xiaoluduan systematicreviewandcumulativeanalysisofthecombinationofmitomycincplusbacilluscalmetteguerinbcgfornonmuscleinvasivebladdercancer AT taozhang systematicreviewandcumulativeanalysisofthecombinationofmitomycincplusbacilluscalmetteguerinbcgfornonmuscleinvasivebladdercancer AT chaocai systematicreviewandcumulativeanalysisofthecombinationofmitomycincplusbacilluscalmetteguerinbcgfornonmuscleinvasivebladdercancer AT guohuazeng systematicreviewandcumulativeanalysisofthecombinationofmitomycincplusbacilluscalmetteguerinbcgfornonmuscleinvasivebladdercancer
_version_	1718384990223335424

Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guérin (BCG) for Non–Muscle-Invasive Bladder Cancer

Ejemplares similares